


## Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults. Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829, 861, 918, 920 & local agreements



Version	3.0
Developed by	Pharmacy and Medicines Optimisation Team, Hertfordshire and West Essex (HWE) ICB
	with relevant HWE ICS stakeholders.
Approved by	Hertfordshire & West Essex Area Prescribing Committee
Date approved / updated	November 2023
Review Date	This HWE APC recommendation is based upon the evidence available at the time of
	publication. This recommendation will be reviewed upon request in the light of new
	evidence becoming available.
Superseded versions	Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults. Treatment
	pathway in line with NICE TAs 383, 407, 497, 718, 719, 829 & local agreements.
	Version 1.0. HWE APC, February 2023
	Pathway for use of biologic drugs for Axial Spondyloarthritis West Essex CCG
	MOPB, October 2021
	Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults.
	Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829 & local
	agreements v1.0 February 2023
	Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults.
	Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829, 861 & local
	agreements v 2.0 March 2023 (bimekizumab & tofacitinib added)